Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a fixed-dose combination of four active pharmaceutical ingredients: **aspirin**, **dexchlorpheniramine**, **phenylephrine**, and **caffeine**. Such combinations are formulated for the symptomatic relief of conditions like the common cold, flu, sinusitis, or allergic rhinitis where headache, nasal congestion, allergic symptoms, and fatigue coexist. **Aspirin** is a non-steroidal anti-inflammatory drug (NSAID) and analgesic that inhibits cyclooxygenases, resulting in reduced pain, fever, and inflammation. **Dexchlorpheniramine** is a first-generation antihistamine that acts as an H1 receptor antagonist, offering relief from allergic symptoms. **Phenylephrine** is a sympathomimetic amine acting as an alpha-1 adrenergic receptor agonist, serving as a decongestant by constricting blood vessels in the nasal mucosa. **Caffeine** is a central nervous system stimulant that can enhance pain relief when combined with analgesics and counteract drowsiness caused by antihistamines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on aspirin + dexchlorpheniramine + phenylephrine + caffeine.